Home » Market News » DirectorsTalk Highlights » Avacta to develop tests that could control spread of coronavirus pandemic
Avacta Group Plc

Avacta to develop tests that could control spread of coronavirus pandemic

Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.

The statement added: “LSTM has been at the forefront of research into infectious, debilitating and disabling diseases since 1898 and was the first institution in the world dedicated to research and teaching in tropical medicine. It has a research portfolio of around £320 million and projects and partnerships in more than 70 countries.”

Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom. The company’s custom Affimer products are also used in drugs and biomarkers discovery in biotech research and development.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.